Corvus Pharmaceuticals (CRVS) Net Cash Flow (2016 - 2026)
Corvus Pharmaceuticals' Net Cash Flow history spans 12 years, with the latest figure at $35.5 million for Q1 2026.
- Quarterly Net Cash Flow rose 1049.64% to $35.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $35.1 million through Mar 2026, up 206.93% year-over-year, with the annual reading at -$4.2 million for FY2025, 7.32% down from the prior year.
- Net Cash Flow came in at $35.5 million for Q1 2026, up from $1.7 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $35.5 million in Q1 2026 to a low of -$32.0 million in Q1 2022.
- The 5-year median for Net Cash Flow is -$3.7 million (2025), against an average of -$3.2 million.
- Year-over-year, Net Cash Flow tumbled 1051.55% in 2024 and then surged 1049.64% in 2026.
- Corvus Pharmaceuticals' Net Cash Flow stood at -$11.4 million in 2022, then soared by 34.51% to -$7.5 million in 2023, then soared by 154.24% to $4.1 million in 2024, then plummeted by 57.91% to $1.7 million in 2025, then skyrocketed by 1978.76% to $35.5 million in 2026.
- Per Business Quant, the three most recent readings for CRVS's Net Cash Flow are $35.5 million (Q1 2026), $1.7 million (Q4 2025), and -$11.8 million (Q3 2025).